The goal of Project 1.2 is to study the role of the chromatin remodeling complex BAF in the transcriptional repression of HIV and in the establishment of latency. We have observed that the chromatin remodeling complex BAF is necessary for the positioning of a single repressive nucleosome (nuc-1) downstream of the HIV transcriptional start site. Inhibition of BAF by selective knockdown of its subunits induces the expression of latent HIV in the J-LAT system. The hypothesis of Project 1.2 is that the BAF chromatin remodeling complex plays a critical role in the maintenance of HIV latency and that interfering with BAF function represents a new therapeutic target for reactivation of latent HIV.
Our aims i n this proposal are: 1. To determine the role of BAF chromatin remodeling complexes on the HIV promoter. The BAF complex, distinguished from the PBAF complex by a unique subunit (BAF250), plays an important role in the repression of basal HIV transcription. We will use chromatin immunoprecipitation to validate the presence of BAF subunits at the repressed HIV promoter and test the role of shRNAs specific for BAF subunits in HIV transcription. We will study the molecular mechanism of recruitment of BAF to the HIV promoter.
Aim 2. To study the role of the BAF complex in HIV latency in primary lymphoid cells. We will collaborate with other members of the Collaboratory (Planelles, Karn, Greene) to define the role of the BAF complex in HIV latency in primary lymphoid cells. We will also explore the biology of the BAF complex in primary lymphoid cells by (1) examining expression of its subunits (mRNA and protein) in resting and activated T cells, (2) knocking down specific subunits and examining patterns of global and HIV gene expression in resting and acti Aim 3. To validate the BAF complex as a therapeutic target for l/E therapy. We will explore BAF as a target for l/E therapy. We will use shRNA or slRNA against different BAF subunits and test their ability to reactivate latent HIV in primary lymphoid model systems for HIV latency and explore possible synergies between l/fe agents and selective BAF subunit knockdown. We will focus this analysis on existing agents, such as SAHA, prostratin and 5-azadeoxycyfidine, and on newer l/E agents developed in this Collaboratory.

Public Health Relevance

Understanding of HIV latency in molecular details represents the first and critical step in generating novel therapies to eliminate the pool of latently-infected cells from HIV-infected patients. We have identified a previously unrecognized cellular complex, called BAF, that plays a critical role in HIV transcriptional repression. These experiments will explore the biological role of the BAF complex in normal lymphocyte biology and in HIV latency and validate the BAF complex as a possible drug target in l/E therapy.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Davis, Zachary B; Cogswell, Andrew; Scott, Hamish et al. (2016) A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog 12:e1005421
Imaz, Arkaitz; Martinez-Picado, Javier; Niubó, Jordi et al. (2016) HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. J Infect Dis 214:1512-1519
Honeycutt, Jenna B; Wahl, Angela; Baker, Caroline et al. (2016) Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest 126:1353-66
Tokarev, Andrey; Stoneham, Charlotte; Lewinski, Mary K et al. (2016) Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1. J Virol 90:2486-502
Victor Garcia, J (2016) Humanized mice for HIV and AIDS research. Curr Opin Virol 19:56-64
Smith, Davey M; Nakazawa, Masato; Freeman, Michael L et al. (2016) Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment. Clin Infect Dis 63:1517-1524
Gianella, Sara; Anderson, Christy M; Var, Susanna R et al. (2016) Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol 90:3944-52
Garcia, J Victor (2016) In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest 126:424-31
Lee, Sook-Kyung; Zhou, Shuntai; Baldoni, Pedro L et al. (2016) Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID In A Viral Outgrowth Assay. J Acquir Immune Defic Syndr :
Wagner, Gabriel A; Chaillon, Antoine; Liu, Siqi et al. (2016) HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS 30:2591-2597

Showing the most recent 10 out of 187 publications